.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AC04_Rilonacept.Rilonacept .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AC04_Rilonacept.Rilonacept| name: | Rilonacept |
| ATC code: | L04AC04 | route: | subcutaneous |
| n-compartments | 1 |
Rilonacept is a dimeric fusion protein acting as an interleukin-1 (IL-1) inhibitor, used primarily in the treatment of cryopyrin-associated periodic syndromes (CAPS), including familial cold autoinflammatory syndrome (FCAS) and Muckle–Wells syndrome (MWS). It is approved for use in the United States for these indications.
Pharmacokinetic parameters reported in adult patients with cryopyrin-associated periodic syndromes who received rilonacept subcutaneously.
Radin, A, et al., & Belomestnov, P (2010). Safety and pharmacokinetics of subcutaneously administered rilonacept in patients with well-controlled end-stage renal disease (ESRD). Journal of clinical pharmacology 50(7) 835–841. DOI:10.1177/0091270009351882 PUBMED:https://pubmed.ncbi.nlm.nih.gov/20035038